MAPT and Alzheimer disease: Nevertheless, available biomarker data demonstrated more AD-like profiles (lower CSF amyloid and higher tau) for APOE4 carriers and CI participants, supporting the interpretation that these individuals were more likely to be in preclinical AD stages.